Jeffrey Hung
Stock Analyst at Morgan Stanley
(3.25)
# 1,030
Out of 4,412 analysts
127
Total ratings
43.82%
Success rate
2.3%
Average return
Main Sectors:
Top Industries:
31 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IRON Disc Medicine | Maintains: Equal-Weight | $75 → $40 | $27.55 | +45.19% | 5 | Apr 2, 2024 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Overweight | $40 → $30 | $16.71 | +79.53% | 16 | Mar 13, 2024 | |
| ENGN enGene Holdings | Initiates: Overweight | $40 | $15.50 | +158.06% | 1 | Mar 8, 2024 | |
| CGON CG Oncology | Initiates: Overweight | $55 | $41.00 | +34.15% | 1 | Feb 20, 2024 | |
| CRNX Crinetics Pharmaceuticals | Initiates: Overweight | $50 | $42.12 | +18.71% | 1 | Jan 16, 2024 | |
| CYTK Cytokinetics | Downgrades: Equal-Weight | $60 → $90 | $65.34 | +37.74% | 6 | Jan 5, 2024 | |
| PTCT PTC Therapeutics | Downgrades: Underweight | $28 | $28.57 | -2.00% | 6 | Dec 19, 2023 | |
| PRLD Prelude Therapeutics | Downgrades: Underweight | $10 → $4 | $4.07 | -1.72% | 7 | Dec 19, 2023 | |
| VIGL Vigil Neuroscience | Downgrades: Underweight | $13 → $4 | $2.71 | +47.60% | 1 | Dec 19, 2023 | |
| RYTM Rhythm Pharmaceuticals | Upgrades: Overweight | $29 → $55 | $38.28 | +43.68% | 9 | Dec 19, 2023 | |
| IVVD Invivyd | Upgrades: Equal-Weight | $1 → $4 | $2.15 | +86.05% | 1 | Dec 19, 2023 | |
| FOLD Amicus Therapeutics | Upgrades: Overweight | $15 → $20 | $10.28 | +94.55% | 1 | Dec 19, 2023 | |
| BLUE bluebird bio | Upgrades: Equal-Weight | $3 → $7 | $0.92 | +658.56% | 1 | Dec 8, 2023 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Overweight | $90 → $84 | $44.24 | +89.87% | 7 | Nov 3, 2023 | |
| BCYC Bicycle Therapeutics | Maintains: Equal-Weight | $42 → $40 | $22.71 | +76.13% | 4 | Nov 3, 2023 | |
| ITCI Intra-Cellular Therapies | Reiterates: Overweight | $80 | $73.26 | +9.20% | 4 | Aug 4, 2023 | |
| IMRX Immuneering | Maintains: Equal-Weight | $14 | $1.47 | +852.38% | 3 | Aug 4, 2023 | |
| NBIX Neurocrine Biosciences | Reiterates: Overweight | $130 | $135.99 | -4.40% | 10 | Aug 2, 2023 | |
| JAZZ Jazz Pharmaceuticals | Reiterates: Equal-Weight | $187 | $109.46 | +70.84% | 3 | Jul 11, 2023 | |
| ADCT ADC Therapeutics | Reiterates: Equal-Weight | $5 | $4.34 | +15.21% | 1 | Jul 11, 2023 | |
| ESPR Esperion Therapeutics | Maintains: Equal-Weight | $9 → $3 | $1.90 | +57.89% | 7 | Mar 20, 2023 | |
| RPTX Repare Therapeutics | Maintains: Equal-Weight | $15 → $14 | $3.20 | +337.50% | 5 | Feb 27, 2023 | |
| CGEM Cullinan Oncology | Maintains: Overweight | $27 → $19 | $25.30 | -24.90% | 4 | Feb 3, 2023 | |
| ERAS Erasca | Upgrades: Overweight | $15 | $1.89 | +693.65% | 2 | Feb 3, 2023 | |
| CELU Celularity | Downgrades: Underweight | $50 → $10 | $3.02 | +231.13% | 3 | Jan 30, 2023 | |
| EXEL Exelixis | Maintains: Equal-Weight | $23 → $22 | $23.70 | -7.17% | 2 | Nov 2, 2022 | |
| EVFM Evofem Biosciences | Maintains: Underweight | $250 → $94 | $0.02 | +559,601.49% | 8 | Jul 15, 2022 | |
| BHVN Biohaven Pharmaceutical Holding Company | Maintains: Equal-Weight | $146 → $149 | $38.97 | +281.06% | 2 | May 11, 2022 | |
| APRE Aprea Therapeutics | Downgrades: Underweight | n/a | $5.20 | - | 3 | Aug 13, 2021 | |
| VYGR Voyager Therapeutics | Maintains: Equal-Weight | n/a | $7.62 | - | 2 | Feb 3, 2021 | |
| NXTC NextCure | Maintains: Overweight | n/a | $1.35 | - | 1 | Apr 15, 2020 |
Disc Medicine
Apr 2, 2024
Maintains: Equal-Weight
Price Target: $75 → $40
Current: $27.55
Upside: +45.19%
ACADIA Pharmaceuticals
Mar 13, 2024
Maintains: Overweight
Price Target: $40 → $30
Current: $16.71
Upside: +79.53%
enGene Holdings
Mar 8, 2024
Initiates: Overweight
Price Target: $40
Current: $15.50
Upside: +158.06%
CG Oncology
Feb 20, 2024
Initiates: Overweight
Price Target: $55
Current: $41.00
Upside: +34.15%
Crinetics Pharmaceuticals
Jan 16, 2024
Initiates: Overweight
Price Target: $50
Current: $42.12
Upside: +18.71%
Cytokinetics
Jan 5, 2024
Downgrades: Equal-Weight
Price Target: $60 → $90
Current: $65.34
Upside: +37.74%
PTC Therapeutics
Dec 19, 2023
Downgrades: Underweight
Price Target: $28
Current: $28.57
Upside: -2.00%
Prelude Therapeutics
Dec 19, 2023
Downgrades: Underweight
Price Target: $10 → $4
Current: $4.07
Upside: -1.72%
Vigil Neuroscience
Dec 19, 2023
Downgrades: Underweight
Price Target: $13 → $4
Current: $2.71
Upside: +47.60%
Rhythm Pharmaceuticals
Dec 19, 2023
Upgrades: Overweight
Price Target: $29 → $55
Current: $38.28
Upside: +43.68%
Invivyd
Dec 19, 2023
Upgrades: Equal-Weight
Price Target: $1 → $4
Current: $2.15
Upside: +86.05%
Amicus Therapeutics
Dec 19, 2023
Upgrades: Overweight
Price Target: $15 → $20
Current: $10.28
Upside: +94.55%
bluebird bio
Dec 8, 2023
Upgrades: Equal-Weight
Price Target: $3 → $7
Current: $0.92
Upside: +658.56%
Ultragenyx Pharmaceutical
Nov 3, 2023
Maintains: Overweight
Price Target: $90 → $84
Current: $44.24
Upside: +89.87%
Bicycle Therapeutics
Nov 3, 2023
Maintains: Equal-Weight
Price Target: $42 → $40
Current: $22.71
Upside: +76.13%
Intra-Cellular Therapies
Aug 4, 2023
Reiterates: Overweight
Price Target: $80
Current: $73.26
Upside: +9.20%
Immuneering
Aug 4, 2023
Maintains: Equal-Weight
Price Target: $14
Current: $1.47
Upside: +852.38%
Neurocrine Biosciences
Aug 2, 2023
Reiterates: Overweight
Price Target: $130
Current: $135.99
Upside: -4.40%
Jazz Pharmaceuticals
Jul 11, 2023
Reiterates: Equal-Weight
Price Target: $187
Current: $109.46
Upside: +70.84%
ADC Therapeutics
Jul 11, 2023
Reiterates: Equal-Weight
Price Target: $5
Current: $4.34
Upside: +15.21%
Esperion Therapeutics
Mar 20, 2023
Maintains: Equal-Weight
Price Target: $9 → $3
Current: $1.90
Upside: +57.89%
Repare Therapeutics
Feb 27, 2023
Maintains: Equal-Weight
Price Target: $15 → $14
Current: $3.20
Upside: +337.50%
Cullinan Oncology
Feb 3, 2023
Maintains: Overweight
Price Target: $27 → $19
Current: $25.30
Upside: -24.90%
Erasca
Feb 3, 2023
Upgrades: Overweight
Price Target: $15
Current: $1.89
Upside: +693.65%
Celularity
Jan 30, 2023
Downgrades: Underweight
Price Target: $50 → $10
Current: $3.02
Upside: +231.13%
Exelixis
Nov 2, 2022
Maintains: Equal-Weight
Price Target: $23 → $22
Current: $23.70
Upside: -7.17%
Evofem Biosciences
Jul 15, 2022
Maintains: Underweight
Price Target: $250 → $94
Current: $0.02
Upside: +559,601.49%
Biohaven Pharmaceutical Holding Company
May 11, 2022
Maintains: Equal-Weight
Price Target: $146 → $149
Current: $38.97
Upside: +281.06%
Aprea Therapeutics
Aug 13, 2021
Downgrades: Underweight
Price Target: n/a
Current: $5.20
Upside: -
Voyager Therapeutics
Feb 3, 2021
Maintains: Equal-Weight
Price Target: n/a
Current: $7.62
Upside: -
NextCure
Apr 15, 2020
Maintains: Overweight
Price Target: n/a
Current: $1.35
Upside: -